NCT04590599View on ClinicalTrials.gov

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

PHASE2CompletedINTERVENTIONAL

Enrollment

205

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2023

Conditions

Advanced Cervical Cancer

Interventions

DRUG

IBI310

IBI310 3 mg/kg,Q3W, for a total of 4 cycles

DRUG

Placebo

Placebo Q3W, for a total of 4 cycles

DRUG

Sintilimab

Sintilimab 200mg,Q3W

Trial Locations (2)

215123

Innovent Biologics, Inc., Suzhou

Unknown

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital）, Zhenjiang

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04590599 - A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy | Biotech Hunter | Biotech Hunter